Agilent Technologies acquires Biovectra for $925M, expanding its biotech services portfolio.
Agilent Technologies has agreed to acquire contract drug manufacturer Biovectra for $925 million, expanding its portfolio of services for biotech companies and medical researchers. Biovectra offers fill-and-finish services and operates a business producing active ingredients for complex drugs. Agilent will fund the transaction using a mix of cash on hand and debt financing, and the deal is expected to close before 2025.
July 22, 2024
8 Articles